Elevated Diabetes Prevalence Fuels Growth In The Macular Edema And Macular Degeneration Market: Strategic Insights Driving Macular Edema and Macular Degeneration Market Momentum in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Macular Edema and Macular Degeneration Market Size By 2025?
The market encompassing macular edema and macular degeneration has experienced substantial expansion recently, projected to increase from a value of $9.65 billion in 2024 to $10.33 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.0%. This historical upward trajectory is primarily linked to several factors, including an increasing elderly demographic, the widespread occurrence of diabetes, enhanced recognition and timely detection of these conditions, worldwide efforts aimed at improving ocular health, advancements in pharmaceutical development, and robust patient support systems.

How Big Is the Macular Edema and Macular Degeneration Market Size Expected to Grow by 2029?
The market encompassing macular edema and macular degeneration is projected to experience robust expansion over the coming years, ing a valuation of $13.44 billion by 2029, reflecting a compound annual growth rate (CAGR) of 6.8%; this upward trajectory is fueled by factors such as the adoption of tailored medical treatments, increasing understanding in developing regions, a greater emphasis on combining different therapeutic methods, the incorporation of remote eye care services, and shifting global age structures.Key developments anticipated within this timeframe encompass progress in drug release mechanisms designed for longevity, the incorporation of genetic treatments, the creation of cutting-edge technologies for visualization, treatment plans customized according to specific biological markers, utilizing remote monitoring via teleophthalmology, and leveraging artificial intelligence capabilities for diagnostic procedures.

View the full report here:
https://www.thebusinessresearchcompany.com/report/macular-edema-and-macular-degeneration-global-market-report

Which Key Market Drivers Powering Macular Edema and Macular Degeneration Market Expansion and Growth?
The increasing prevalence of diabetes is projected to stimulate the expansion of the market for macular edema and macular degeneration. Diabetes, a persistent health issue defined by elevated blood sugar concentrations, causes harm to the ocular blood vessels, leading potentially to both macular edema and macular degeneration. As an illustration, data from The National Health Service (NHS England), a UK healthcare entity funded by public means, revealed for June 2024 that the count of people in England diagnosed with pre-diabetes ed 3,615,330 in 2023, which represents an 18 percent jump compared to the 3,065,825 cases recorded in 2022; furthermore, within the demographic under the age of forty, instances escalated by almost 25 percent, moving from 173,166 in 2022 to 216,440 the following year. Consequently, this escalating diabetic population acts as a catalyst for the development of the macular edema and macular degeneration market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Macular Edema and Macular Degeneration Market?
Key players within the macular edema and macular degeneration arena are concentrating efforts on pioneering novel therapeutic options, exemplified by Vabysmo (faricimab-svoa), with the aim of enhancing their financial returns in this sector. This specific agent, Vabysmo (faricimab-svoa), is indicated for managing both diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). A notable event occurred in January 2022 when Genentech Inc., an American biotech firm, secured authorization for Vabysmo (faricimab-svoa) from the Food and Drug Administration; this drug distinguishes itself as the inaugural bispecific monoclonal antibody approved for these two conditions because it potently neutralizes both angiopoietin 2 (Ang-2) and vascular endothelial growth factor (VEGF). The regulatory endorsements received from the FDA and the European Union mark a substantial achievement for both Roche and Genentech, positioning faricimab as a potentially top-selling medication for DME and nAMD treatment regimes.

What Are the Emerging Segments in the Macular Edema and Macular Degeneration Market?
The macular edema and macular degenerationmarket covered in this report is segmented -

1) By Treatment Type: Drug Therapy; Laser Treatment
2) By Application: Macular Edema; Diabetic Macular Edema (DME); Cystoid Macular Edema (CME); Macular Degeneration; Dry age-related macular degeneration; Wet age-related macular degeneration
3) By End User: Hospitals; Clinics; Other End Users

Subsegments:
1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections; Steroid Injections; Oral Medications; Combination Therapy (Anti-VEGF + Steroids)
2) By Laser Treatment: Focal Laser Photocoagulation; Panretinal Photocoagulation (PRP); Subthreshold Laser Therapy; MicroPulse Laser Therapy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13479&type=smp

Who Are the Global Leaders in the Macular Edema and Macular Degeneration Market?
Major companies operating in the macular edema and macular degeneration market report are F. Hoffmann La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Bausch Health Companies Inc., Clover Therapeutics Inc., Santen Pharmaceutical Co. Ltd., Samsung Bioepis Inc., PanOptica Inc., Regen X Bio Inc., Aerie Pharmaceutical Inc., Apellis Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd., Alimera Sciences Inc., Kodiak Sciences Inc., Acucela Inc., Editas Medicine Inc., IVERIC bio Inc., Lineage Cell Therapeutics Inc., Allegro Ophthalmic Ltd., Ampio Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Graybug Vision Inc., Clearside Biomedical Inc., Ocugen Inc., Opthea Limited

Which are the Top Profitable Regional Markets for the Macular Edema and Macular Degeneration Industry?
North America was the largest region in the macular edema and macular degeneration market in 2024. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13479

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.